S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Ono Pharmaceutical Stock Forecast, Price & News

0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $29.70
50-Day Range
MA: $29.50
52-Week Range
Now: $29.70
Average Volume600 shs
Market Capitalization$15.27 billion
P/E Ratio27.00
Dividend YieldN/A
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A



Sales & Book Value

Annual Sales$2.69 billion
Cash Flow$1.35 per share
Book Value$10.16 per share


Net Income$549.28 million


Market Cap$15.27 billion
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.07 out of 5 stars

Medical Sector

982nd out of 1,972 stocks

Pharmaceutical Preparations Industry

462nd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPHLF News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHLF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ono Pharmaceutical (OTCMKTS:OPHLF) Frequently Asked Questions

What stocks does MarketBeat like better than Ono Pharmaceutical?

Wall Street analysts have given Ono Pharmaceutical a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ono Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 400,800 shares, an increase of 137.3% from the January 28th total of 168,900 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is currently 1,002.0 days.
View Ono Pharmaceutical's Short Interest

When is Ono Pharmaceutical's next earnings date?

Ono Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Ono Pharmaceutical

How has Ono Pharmaceutical's stock been impacted by COVID-19?

Ono Pharmaceutical's stock was trading at $22.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPHLF stock has increased by 35.0% and is now trading at $29.70.
View which stocks have been most impacted by COVID-19

Who are Ono Pharmaceutical's key executives?

Ono Pharmaceutical's management team includes the following people:
  • Mr. Gyo Sagara, CEO, Pres & Representative Director
  • Mr. Shozo Matsuoka, Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
  • Yukio Tani, Corp. Exec. Officer & Head of Corp. Communications
  • Mr. Hiroshi Ichikawa, Corp. Sr. Exec. Officer and Exec. Director of Sales & Marketing
  • Mr. Isao Ono, Exec. Officer, Director of Corp. Research & Director
  • Mr. Hiroshi Awata, VP, Exec. Officer, Tokyo Branch Head & Director
  • Mr. Toichi Takino, Exec. Officer, Exec. Director of Discovery & Research and Director
  • Mr. Toshihiro Tsujinaka, Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director
  • Kiyoaki Idemitsu, Corp. Exec. Officer & Exec. Director of Clinical Devel.
  • Shinji Takai M.D., Corp. Officer, Head of Medical Affairs & Head of Data Strategy

Who are some of Ono Pharmaceutical's key competitors?

What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ono Pharmaceutical's stock price today?

One share of OPHLF stock can currently be purchased for approximately $29.70.

How much money does Ono Pharmaceutical make?

Ono Pharmaceutical has a market capitalization of $15.27 billion and generates $2.69 billion in revenue each year. The company earns $549.28 million in net income (profit) each year or $1.09 on an earnings per share basis.

How many employees does Ono Pharmaceutical have?

Ono Pharmaceutical employs 3,560 workers across the globe.

What is Ono Pharmaceutical's official website?

The official website for Ono Pharmaceutical is www.ono.co.jp.

Where are Ono Pharmaceutical's headquarters?

Ono Pharmaceutical is headquartered at 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564.

How can I contact Ono Pharmaceutical?

Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The company can be reached via phone at 816-6263-5670.

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.